Company / Revenue
Clearside Biomedical, Inc. Revenue History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$1.7M
FY2024
5-year range
$1.3M / $29.6M
FY2020-FY2024
Trend
-79.8%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue has fluctuated over the past 7 years, ranging from $30,000 in FY2018 to $30M in FY2021.
Based on SEC 10-K filings.
$2M in FY2024 with a 5-year CAGR of -5.2%.
Improved from $1M to $2M over the past 2 years.
Revenue over time
Growth rates
- 3-Year CAGR
- -61.7%
- 5-Year CAGR
- -5.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -5.2%, indicating a declining trend.
- In FY2024, revenue decreased 79.8% year-over-year.
- Peak revenue was recorded in FY2021.
- Lowest revenue in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -15.27 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $1.7M | -79.8% |
| FY2023 | $8.2M | +519.9% |
| FY2022 | $1.3M | -95.5% |
| FY2021 | $29.6M | +274.7% |
| FY2020 | $7.9M | +263.3% |
| FY2019 | $2.2M | +7143.3% |
| FY2018 | $30.0K | - |
As of FY2024 · SEC 10-K · Updated Jun 29, 2026